NRD
KALV

Nebula Research & Development’s KalVista Pharmaceuticals KALV Stock Holding History

Nebula Research & Development’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-11,579
Closed -$98.1K – 1045
2024
Q4 		$98.1K Buy
+11,579
New +$120K 0.01% 856

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Nebula Research & Development's KALV Position: Q1 2025 in Review

Nebula Research & Development sold out of KalVista Pharmaceuticals (KALV) in Q1 2025, closing a stake of 11,579 shares — an estimated $98.1K sold.

Nebula Research & Development first reported a position in KALV in Q4 2024 and held it in 1 quarter. The position peaked at $98.1K in Q4 2024. 128 funds tracked by Wall St. Rank hold KALV as of Q1 2025.

  • Nebula Research & Development reported no remaining KalVista Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Nebula Research & Development sold 11,579 KalVista Pharmaceuticals shares in Q1 2025, an estimated $98.1K.
  • Nebula Research & Development first reported a position in KalVista Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Nebula Research & Development's KalVista Pharmaceuticals position peaked at $98.1K in Q4 2024.
  • 128 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2025.

Based on Nebula Research & Development's 13F filing for Q1 2025, filed 15 May 2025.